Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia
- 1 May 1981
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 73 (4) , 359-362
- https://doi.org/10.1007/bf00426466
Abstract
Thirty inpatients with evidence of tardive dyskinesia secondary to antipsychotic medications participated in this double-blind, controlled, randomized study comparing reserpine, α-methyldopa and placebo. Reserpine at doses of 0.75–1.5 mg daily, or α-methyldopa at doses of 750–1,500 mg daily, produced a statistically significant improvement in tardive dyskinesia symptomatology compared to the results obtained with placebo.This publication has 20 references indexed in Scilit:
- Effects of alternative transmitter amines on cyclic AMP formation in rat brain tissueEuropean Journal of Pharmacology, 1979
- Mediocre Effects of Reserpine on Tardive DyskinesiaNew England Journal of Medicine, 1973
- Treatment of Tardive DyskinesiaArchives of General Psychiatry, 1972
- Treatment of Tardive DyskinesiaArchives of General Psychiatry, 1972
- THEORETICAL IMPLICATIONS OF THE USE OF L-DOPA IN PARKINSONISM.Acta Neurologica Scandinavica, 1970
- TREATMENT OF DRUG-INDUCED DYSKINESIASThe Lancet, 1970
- Effect of alpha-methyl dopa and reserpine in huntington's chorea, parkinson's disease and other movement disordersLife Sciences, 1963
- THE ACTION OF SOME α‐METHYL AND OTHER AMINO ACIDS ON CEREBRAL CATECHOLAMINES*Journal of Neurochemistry, 1961
- DEPRESSION BY RESERPINE OF THE NORADRENALINE CONCENTRATION IN THE HYPOTHALAMUS OF THE CATJournal of Neurochemistry, 1956
- Serotonin Release as a Possible Mechanism of Reserpine ActionScience, 1955